Daiichi Sankyo Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
20,171
- Stock Symbol
-
4568
- Investments
-
20
- Share Price
-
$17.84
- (As of Friday Closing)
Daiichi Sankyo General Information
Description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
Contact Information
Website
www.daiichisankyo.comCorporate Office
- 3-5-1, Nihonbashi-honcho
- Chuo-ku
- Tokyo, 103-8426
- Japan
Corporate Office
- 3-5-1, Nihonbashi-honcho
- Chuo-ku
- Tokyo, 103-8426
- Japan
Daiichi Sankyo Stock Performance
As of 13-Nov-2026, Daiichi Sankyo’s stock price is $17.84. Its current market cap is $32.5B with 1.82B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.84 | $17.89 | $14.94 - $25.05 | $32.5B | 1.82B | 7.09M | $0.97 |
Daiichi Sankyo Financials Summary
As of 30-Sep-2026, Daiichi Sankyo has a trailing 12-month revenue of $14.7B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 31,287,383 | 29,349,150 | 39,480,426 | 53,073,618 |
| Revenue | 14,708,788 | 14,085,561 | 12,369,044 | 11,085,126 |
| EBITDA | 2,311,388 | 2,043,876 | 2,636,301 | 1,878,464 |
| Net Income | 1,782,865 | 1,724,161 | 1,939,408 | 1,389,240 |
| Total Assets | 27,053,322 | 25,055,925 | 23,095,861 | 22,868,418 |
| Total Debt | 3,178,412 | 1,879,675 | 677,161 | 672,038 |
Daiichi Sankyo Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Daiichi Sankyo Comparisons
Industry
Financing
Details
Daiichi Sankyo Competitors (55)
One of Daiichi Sankyo’s 55 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Celldex | Formerly VC-backed | Hampton, NJ | ||||
| Genmab | Formerly VC-backed | Valby, Denmark | ||||
| Shionogi | Corporation | Osaka, Japan | ||||
| Immatics | Formerly VC-backed | Tuebingen, Germany |
Daiichi Sankyo Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Daiichi Sankyo Patents
Daiichi Sankyo Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026230546-A1 | Method for treating fibrosis | Pending | 30-Apr-2025 | ||
| WO-2026230489-A1 | Combination of antibody-drug conjugate and t-cell-recruiting antibody | Pending | 28-Apr-2025 | ||
| EP-4830787-A1 | Combination therapy with an anti cd147 antibody and an anti trop2 antibody drug conjugate and/or an anti her2 antibody drug conjugate | Pending | 25-Apr-2025 | ||
| WO-2026217084-A1 | Combinations for the treatment of small cell lung cancer | Pending | 07-Apr-2025 | ||
| WO-2026217450-A1 | Combinations for the treatment of small cell lung cancer | Pending | 07-Apr-2025 |
Daiichi Sankyo Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Daiichi Sankyo Investments & Acquisitions (20)
Daiichi Sankyo’s most recent deal was a Secondary Transaction - Private with Noetra. The deal was made on 16-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Noetra | 16-Jul-2026 | Secondary Transaction - Private | Business/Productivity Software | ||
| Ultragenyx Pharmaceutical | 31-Mar-2020 | PIPE | Biotechnology | ||
| Cuorips | 11-Jul-2018 | Seed Round | Biotechnology | ||
| Glycotope (Global Rights to Develop Gatipotuzumab Antibody-Drug Conjugates) | 30-Jun-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Rice Force | 02-Oct-2015 | Merger/Acquisition | Personal Products |
Daiichi Sankyo ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
18.31 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Daiichi Sankyo Exits (10)
Daiichi Sankyo’s most recent exit was on 31-Mar-2020 from Ultragenyx Pharmaceutical. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical | 31-Mar-2020 | Completed |
|
||
| Cuorips | 11-Jul-2018 | Completed |
|
||
| Zenotech Laboratories | 01-Jan-2014 | Completed |
|
||
| Orphan Disease Treatment Institute | 14-Feb-2013 | Completed |
|
||
| Coherus Oncology | 10-Mar-2011 | Early Stage VC | Completed |
|
Daiichi Sankyo Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Daiichi Sankyo Healthcare | Tokyo, Japan | 2005 | |
| U3 Pharma | Planegg, Germany | 2001 | |
| American Regent | Shirley, NY | 1967 |
Daiichi Sankyo FAQs
-
When was Daiichi Sankyo founded?
Daiichi Sankyo was founded in 2005.
-
Where is Daiichi Sankyo headquartered?
Daiichi Sankyo is headquartered in Tokyo, Japan.
-
What is the size of Daiichi Sankyo?
Daiichi Sankyo has 20,171 total employees.
-
What industry is Daiichi Sankyo in?
Daiichi Sankyo’s primary industry is Biotechnology.
-
Is Daiichi Sankyo a private or public company?
Daiichi Sankyo is a Public company.
-
What is Daiichi Sankyo’s stock symbol?
The ticker symbol for Daiichi Sankyo is 4568.
-
What is the current stock price of Daiichi Sankyo?
As of 13-Nov-2026 the stock price of Daiichi Sankyo is $17.84.
-
What is the current market cap of Daiichi Sankyo?
The current market capitalization of Daiichi Sankyo is $32.5B.
-
What is Daiichi Sankyo’s current revenue?
The trailing twelve month revenue for Daiichi Sankyo is $14.7B.
-
Who are Daiichi Sankyo’s competitors?
Astellas Pharma, Celldex, Genmab, Shionogi, and Immatics are some of the 55 competitors of Daiichi Sankyo.
-
What is Daiichi Sankyo’s annual earnings per share (EPS)?
Daiichi Sankyo’s EPS for 12 months was $0.97.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
